Selected demographic, clinical, and outcome variables for S9400 patients included in the Q-RT-PCR analysis, by CTGF expression level tertile
| Variable . | CTGF expression . | Total . | ||
|---|---|---|---|---|
| Low . | Intermediate . | High . | ||
| No. of patients | 27 | 26 | 26 | 79 |
| Median age, y (range) | 31 (18-59) | 32 (17-62) | 41 (18-64) | 35 (17-64) |
| FAB, no. (%) | ||||
| L1 | 9 (33) | 6 (23) | 8 (31) | 23 (29) |
| L2 | 16 (59) | 17 (65) | 18 (69) | 51 (65) |
| NA | 2 (7) | 3 (12) | 0 (0) | 5 (6) |
| Lineage, no. (%) | ||||
| T | 9 (33) | 3 (12) | 1 (4) | 13 (13) |
| B | 11 (41) | 19 (73) | 20 (77) | 50 (63) |
| NA | 7 (26) | 4 (15) | 5 (19) | 16 (20) |
| Performance status, no. (%) | ||||
| 0 | 13 (48) | 14 (54) | 12 (46) | 39 (49) |
| 1 | 11 (41) | 9 (35) | 14 (54) | 34 (43) |
| 2 | 2 (7) | 1 (4) | 0 (0) | 3 (4) |
| NA | 1 (4) | 2 (8) | 0 (0) | 3 (4) |
| Median WBC count, × 109/L (range) | 19.5 (2.1-396.6) | 27.3 (0.6-148.0) | 28.4 (3.3-150.0) | 23.4 (0.6-396.6) |
| Median PB blasts, % (range)* | 49 (1-96) | 60 (0-94) | 48 (0-95) | 56 (0-96) |
| Median BM blasts, % (range)† | 80 (31-99) | 94 (72-99) | 90 (58-99) | 90 (31-99) |
| CD34, % positive cells‡ | 8 (0-96) | 51 (1-95) | 81 (8-98) | 64 (0-98) |
| Cytogenetics, no. (%) | ||||
| UNF | 3 (11) | 12 (46) | 10 (38) | 25 (32) |
| NL | 6 (22) | 3 (12) | 4 (15) | 13 (16) |
| Others | 14 (52) | 7 (27) | 2 (8) | 23 (29) |
| NA | 4 (15) | 4 (15) | 10 (38) | 18 (23) |
| Complete response, no. (%) | 21 (81) | 22 (85) | 21 (81) | 64 (82) |
| Resistant disease, no. (%) | 1 (4) | 2 (8) | 3 (12) | 6 (8) |
| 5-y overall survival, % (95% CI) | 58 (38-78) | 42 (23-61) | 11 (0-24) | 37 (26-48) |
| 5-y disease-free survival,§ % (95% CI) | 54 (32-76) | 41 (20-61) | 5 (0-14) | 33 (21-45) |
| Variable . | CTGF expression . | Total . | ||
|---|---|---|---|---|
| Low . | Intermediate . | High . | ||
| No. of patients | 27 | 26 | 26 | 79 |
| Median age, y (range) | 31 (18-59) | 32 (17-62) | 41 (18-64) | 35 (17-64) |
| FAB, no. (%) | ||||
| L1 | 9 (33) | 6 (23) | 8 (31) | 23 (29) |
| L2 | 16 (59) | 17 (65) | 18 (69) | 51 (65) |
| NA | 2 (7) | 3 (12) | 0 (0) | 5 (6) |
| Lineage, no. (%) | ||||
| T | 9 (33) | 3 (12) | 1 (4) | 13 (13) |
| B | 11 (41) | 19 (73) | 20 (77) | 50 (63) |
| NA | 7 (26) | 4 (15) | 5 (19) | 16 (20) |
| Performance status, no. (%) | ||||
| 0 | 13 (48) | 14 (54) | 12 (46) | 39 (49) |
| 1 | 11 (41) | 9 (35) | 14 (54) | 34 (43) |
| 2 | 2 (7) | 1 (4) | 0 (0) | 3 (4) |
| NA | 1 (4) | 2 (8) | 0 (0) | 3 (4) |
| Median WBC count, × 109/L (range) | 19.5 (2.1-396.6) | 27.3 (0.6-148.0) | 28.4 (3.3-150.0) | 23.4 (0.6-396.6) |
| Median PB blasts, % (range)* | 49 (1-96) | 60 (0-94) | 48 (0-95) | 56 (0-96) |
| Median BM blasts, % (range)† | 80 (31-99) | 94 (72-99) | 90 (58-99) | 90 (31-99) |
| CD34, % positive cells‡ | 8 (0-96) | 51 (1-95) | 81 (8-98) | 64 (0-98) |
| Cytogenetics, no. (%) | ||||
| UNF | 3 (11) | 12 (46) | 10 (38) | 25 (32) |
| NL | 6 (22) | 3 (12) | 4 (15) | 13 (16) |
| Others | 14 (52) | 7 (27) | 2 (8) | 23 (29) |
| NA | 4 (15) | 4 (15) | 10 (38) | 18 (23) |
| Complete response, no. (%) | 21 (81) | 22 (85) | 21 (81) | 64 (82) |
| Resistant disease, no. (%) | 1 (4) | 2 (8) | 3 (12) | 6 (8) |
| 5-y overall survival, % (95% CI) | 58 (38-78) | 42 (23-61) | 11 (0-24) | 37 (26-48) |
| 5-y disease-free survival,§ % (95% CI) | 54 (32-76) | 41 (20-61) | 5 (0-14) | 33 (21-45) |
NA indicates not available; UNF, unfavorable; NL, normal; CI, confidence interval.
N = 74.
N = 64.
N = 67.
Disease-free survival was measured from the date the complete response was established until relapse of leukemia or death from any cause, with observations censored for patients last known to be alive without report of relapse.